Content Compliancy Policy

Our principles
• Patient-first - we don't “sell” medicines; we provide consultations and advice, and prescribe only where clinically appropriate.
• Clinically reviewed - health content is reviewed by a qualified clinician before publication and on a regular schedule after that.
• Transparent and balanced - we present benefits, risks and uncertainties clearly, without hype.
• Evidence-led - claims are supported by reputable sources such as the BNF, NICE guidance and peer-reviewed evidence.
• Accountable - pages show when they were written, reviewed and last updated.

How we talk about our services
In line with UK rules on advertising medicines, we do not advertise prescription-only medicines to the public. We describe the service consultation, clinical assessment and, where appropriate, prescribing rather than promoting specific products, and we avoid promotional language (for example, we won't call a medicine “the best”) or anything implying an impulse purchase or discount on a prescription-only medicine.

Sources we rely on
Typical reference sources include:
• British National Formulary (BNF) and Electronic Medicines Compendium (SmPCs/PILs).
• NICE guidance and technology appraisals.
• Peer-reviewed evidence (e.g. Cochrane reviews) and major clinical trials.
• MHRA Drug Safety Updates and relevant professional standards (e.g. Royal Pharmaceutical Society frameworks).

Regulatory frameworks we align to
• GPhC guidance for registered pharmacies providing services at a distance.
• MHRA / Human Medicines Regulations rules on advertising medicines to the public.
• ASA/CAP Code (advertising standards), including Section 12 on medicines and health.
• ICO guidance on UK GDPR and special category (health) data.

Governance and review
Content is checked for clinical accuracy and plain-English readability before publishing, and reviewed at least every [12 months], or sooner if guidance changes. If you spot an error or have a concern, please contact us at [contact email]; urgent safety concerns are escalated immediately to our clinical governance lead.

What we will never do
• Advertise prescription-only medicines directly to the public.
• Use superlatives or exaggerate effectiveness.
• Hide risks or cherry-pick data.
• Publish health content that hasn't been clinically reviewed.